These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36745163)

  • 1. Contingency Management for Stimulant Use Disorder: Progress, Challenges, and Recommendations.
    Rawson RA; Erath TG; Chalk M; Clark HW; McDaid C; Wattenberg SA; Roll JM; McDonell MG; Parent S; Freese TE
    J Ambul Care Manage; 2023 Apr-Jun 01; 46(2):152-159. PubMed ID: 36745163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fourth wave of the overdose crisis: Examining the prominent role of psychomotor stimulants with and without fentanyl.
    Rawson RA; Erath TG; Clark HW
    Prev Med; 2023 Nov; 176():107625. PubMed ID: 37468073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The national implementation of Contingency Management (CM) in the Department of Veterans Affairs: Attendance at CM sessions and substance use outcomes.
    DePhilippis D; Petry NM; Bonn-Miller MO; Rosenbach SB; McKay JR
    Drug Alcohol Depend; 2018 Apr; 185():367-373. PubMed ID: 29524874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptation of contingency management for stimulant use disorder during the COVID-19 pandemic.
    Zastepa E; Sun JC; Clune J; Mathew N
    J Subst Abuse Treat; 2020 Nov; 118():108102. PubMed ID: 32854983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applying behavioral activation to sustain and enhance the effects of contingency management for reducing stimulant use among individuals with HIV infection.
    Mimiaga MJ; Closson EF; Pantalone DW; Safren SA; Mitty JA
    Psychol Health Med; 2019 Mar; 24(3):374-381. PubMed ID: 30211620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Acute Care Contingency Management Program for the Treatment of Stimulant Use Disorder: A Case Report.
    Bach P; Garrod E; Robinson K; Fairbairn N
    J Addict Med; 2020 Dec; 14(6):510-513. PubMed ID: 32142054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient characteristics and treatment utilization in fatal stimulant-involved overdoses in the United States Veterans Health Administration.
    Coughlin LN; Zhang L; Bohnert ASB; Maust DT; Goldstick J; Lin LA
    Addiction; 2022 Apr; 117(4):998-1008. PubMed ID: 34648209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide dissemination of contingency management: the Veterans Administration initiative.
    Petry NM; DePhilippis D; Rash CJ; Drapkin M; McKay JR
    Am J Addict; 2014; 23(3):205-10. PubMed ID: 24724876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis.
    Ciccarone D
    Curr Opin Psychiatry; 2021 Jul; 34(4):344-350. PubMed ID: 33965972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.
    Peirce JM; Petry NM; Stitzer ML; Blaine J; Kellogg S; Satterfield F; Schwartz M; Krasnansky J; Pencer E; Silva-Vazquez L; Kirby KC; Royer-Malvestuto C; Roll JM; Cohen A; Copersino ML; Kolodner K; Li R
    Arch Gen Psychiatry; 2006 Feb; 63(2):201-8. PubMed ID: 16461864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from statewide contingency management rollouts addressing stimulant use in the Northwestern United States.
    Parent SC; Peavy KM; Tyutyunnyk D; Hirchak KA; Nauts T; Dura A; Weed L; Barker L; McDonell MG
    Prev Med; 2023 Nov; 176():107614. PubMed ID: 37451553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of stimulant use disorder: A systematic review of reviews.
    Ronsley C; Nolan S; Knight R; Hayashi K; Klimas J; Walley A; Wood E; Fairbairn N
    PLoS One; 2020; 15(6):e0234809. PubMed ID: 32555667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness.
    McDonell MG; Srebnik D; Angelo F; McPherson S; Lowe JM; Sugar A; Short RA; Roll JM; Ries RK
    Am J Psychiatry; 2013 Jan; 170(1):94-101. PubMed ID: 23138961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness.
    Murphy SM; McDonell MG; McPherson S; Srebnik D; Angelo F; Roll JM; Ries RK
    Drug Alcohol Depend; 2015 Aug; 153():293-9. PubMed ID: 26026494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between pre-treatment drug use and heterogeneity of psychiatric diagnosis predicts outcomes in outpatients with co-occurring disorders.
    Oluwoye O; Hirchak K; Leickly E; Skalisky J; McPherson S; Srebnik D; Roll JM; Ries RK; McDonell MG
    Psychiatry Res; 2018 Feb; 260():233-235. PubMed ID: 29220679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining Longitudinal Stimulant Use and Treatment Attendance as Parallel Outcomes in Two Contingency Management Randomized Clinical Trials.
    McPherson S; Brooks O; Barbosa-Leiker C; Lederhos C; Lamp A; Murphy S; Layton M; Roll J
    J Subst Abuse Treat; 2016 Feb; 61():18-25. PubMed ID: 26456717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulant safe supply: a potential opportunity to respond to the overdose epidemic.
    Fleming T; Barker A; Ivsins A; Vakharia S; McNeil R
    Harm Reduct J; 2020 Jan; 17(1):6. PubMed ID: 31924209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An implementation-focused process evaluation of an incentive intervention effectiveness trial in substance use disorders clinics at two Veterans Health Administration medical centers.
    Hagedorn HJ; Stetler CB; Bangerter A; Noorbaloochi S; Stitzer ML; Kivlahan D
    Addict Sci Clin Pract; 2014 Jul; 9(1):12. PubMed ID: 25008457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing stimulant use disorder through state opioid response grants from the substance abuse and mental health services administration: Missouri's initial approach.
    Winograd RP; Weinstock J; Ruiz A; Coffey B; Brown K; Kondai R; Connors E; Smith C
    Am J Drug Alcohol Abuse; 2022 Nov; 48(6):644-650. PubMed ID: 35881885
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.